Sector: Life Sciences

Latest content

Validity rate for Chinese patents ticks upward, but patent owners in top tech areas face tough road

While more than half of invention patents survive invalidation unscathed, key life science and communications classes see higher knock-out rate

06 December 2021

Australia under-invests in IP, and recent government proposals will not fix that

Saturday Opinion: In-house leaders say a mooted patent box regime limited to life sciences will reward companies that get patents already, failing to encourage IP investment in new industries

04 December 2021

CAFC tees up patent fight over multi-billion-dollar Moderna covid revenues

Arbutus Biopharma’s shares soar in anticipation of mRNA jab royalty lawsuit after Federal Circuit ruling

03 December 2021

Federal Circuit confirms Biogen’s multi-billion dollar Tecfidera patent disaster

In a split decision, the CAFC has upheld a decision that cut short the exclusivity of the company’s best-selling product by eight years

02 December 2021

China patent term extensions create new pitfalls for pharma innovators

Life sciences IP professionals must work closer than ever before with regulatory teams to ensure eligibility for lucrative exclusivity add-ons

30 November 2021

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

29 November 2021

USPTO rejections: post-Alice insights

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

CNIPA's draft patent examination guidelines: what is coming down the pipeline?

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Strategic patent countries: evidence from EPO oppositions

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Abandonments in 2020: an in-depth look

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Get unlimited access to all IAM content